Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. - Wikidata - awgldk - TriplyDB

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

http://www.wikidata.org/entity/Q48400110

about

Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development Creatine for women in pregnancy for neuroprotection of the fetus Creatine for Parkinson's disease Creatine for Parkinson's disease The role of oxidative stress in Parkinson's disease Nutraceuticals in Parkinson's Disease A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions Oxidative Stress in Neurodegenerative Diseases Creatine supplementation during pregnancy: summary of experimental studies suggesting a treatment to improve fetal and neonatal morbidity and reduce mortality in high-risk human pregnancy Mitochondrial dysfunction and oxidative stress in Parkinson's disease Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes.C. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan Extension The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.Brain imaging and human nutrition: which measures to use in intervention studies?Potential future neuroprotective therapies for neurodegenerative disorders and stroke.The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine A potential role for creatine in drug abuse?Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives.Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone.Stuck at the bench: Potential natural neuroprotective compounds for concussion.Early Expression of Parkinson's Disease-Related Mitochondrial Abnormalities in PINK1 Knockout Rats.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Does creatine supplementation improve the plasma lipid profile in healthy male subjects undergoing aerobic training?Progress in neuroprotection in Parkinson's disease.Protection against Parkinson's disease progression: clinical experience.Therapy development for ALS: lessons learned and path forward.Efficient GSH delivery using PAMAM-GSH into MPP-induced PC12 cellular model for Parkinson's disease.Targets for neuroprotection in Parkinson's disease Mitochondrial approaches for neuroprotection Role of creatine supplementation on exercise-induced cardiovascular function and oxidative stress.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease.Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.Creatine in mouse models of neurodegeneration and aging.

P2860

Q22241837-A24DC273-D8A9-437A-A483-2B74F909CA45 Q24187191-D1A526AF-59CF-44F4-A6B0-ECC9B3C11DEF Q24193947-C536E8B4-417A-4805-90A8-5EA831698988 Q24203799-7864BECE-9BE8-4A17-9191-A2CF9F4BAAA9 Q24307946-42C9641B-6C5B-4FE9-81D6-F3C7E97F84AC Q26752769-56319083-3A88-49DC-9244-4DAF0209C93A Q26781560-C79C9830-1B95-47D6-B805-594DD96326DD Q26801239-E3068D12-ADA2-4B18-81DB-0415ADD1A9CD Q27006952-C82E61F7-C325-4226-917C-9E2545FC2FE7 Q27014051-2959A1E4-EC85-4C78-82F7-CA6A1E22DF93 Q28084254-712E2191-0A57-4479-B080-C50B9970EC8A Q28386769-227F2293-D03F-47D3-A22E-C215F596D872 Q28601083-C8281B96-06B6-43D5-A026-C055AE552E73 Q30635471-6C68B8AE-F95C-49CE-9305-CF3602B9B360 Q30658391-F508E6D7-D3B3-4F38-9F83-9379C64A4568 Q33687436-AB9526BB-EAA8-47A0-B050-81888DF22C59 Q33760040-B71E20AA-6834-4F87-8D5C-B8F6C98BA9BF Q33791877-E89FB048-020D-463F-91D1-117472BE5125 Q33844763-87D7616B-2725-4C21-9D2F-C0D769F521A4 Q34089086-94775B22-5BFC-47F3-8304-61575BE9183A Q34460675-81DF80B6-0642-42D7-96F2-46A3CEF7E046 Q35045060-51F2A8C8-D398-4A41-8BF4-CDFD599BFA47 Q35493114-5DC1C675-3B4F-4170-A8F2-55BCEB6EB0DA Q35642539-BC5E63E5-D967-48CE-AA77-A5F7714B13B7 Q35958359-84327652-DD73-49CF-841F-37DF4380ADFD Q36499640-DD555E1E-99B4-4AE8-8D8F-C4C1C25E7FC7 Q36975082-2D9328E2-4422-4A34-B48E-6E98058401DC Q37114112-EB6485FE-D97C-4370-971A-923EC7B53549 Q37131239-8884E376-5F29-46D1-A9E1-6D866A2216C5 Q37198692-EE8B8790-38FA-4690-9AD4-BF6B8E988C92 Q37298397-8843D696-04FB-4FE3-840F-515FB7FAC49F Q37302453-CB0E635E-74A6-4D18-A6A2-3B15C44232C2 Q37348590-63962534-F41C-4151-9675-B6DE4FFE7E9D Q37390314-DC564C6A-CBCB-41D5-BF4F-2B4DC7BED270 Q37506492-C75D529D-D804-40DD-970F-782A765B8FE8 Q37539279-BCECA6FC-BAD7-40DA-83A9-3F8FE38906D5 Q37580731-1507D214-DB57-4EA2-BE02-B08E18FA2315 Q37653023-1E3475B8-B4EE-4201-B942-D10B69202912 Q37698597-3FFFA1AA-229D-4E66-B3A7-C1885A25AD9A Q37851389-9ED3124E-82C4-414A-8554-56F3B0B5C7C2

P2860

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

http://www.wikidata.org/entity/Q48400110

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Creatine supplementation in Pa ...... rolled randomized pilot trial.

@en

Creatine supplementation in Pa ...... rolled randomized pilot trial.

@nl

type

label

Creatine supplementation in Pa ...... rolled randomized pilot trial.

@en

Creatine supplementation in Pa ...... rolled randomized pilot trial.

@nl

prefLabel

Creatine supplementation in Pa ...... rolled randomized pilot trial.

@en

Creatine supplementation in Pa ...... rolled randomized pilot trial.

@nl

P1433

Q48400110-E57BA46F-E411-44AF-968F-DBBA41E28D80

P1476

Q48400110-ABA7F37C-A31D-4485-854E-6CEB1C3B389F

P2093

Q48400110-34F8D128-5A1A-4CF1-AD9E-6EFDAF0D2F62

Q48400110-46D6DD1B-8895-41F9-AFC4-0F72C6726199

Q48400110-4DD7A233-58A4-4AAB-857F-C21D6D578BCA

Q48400110-51C18E9B-7E1C-4664-A4C2-54D0D43CF20B

Q48400110-56821DA2-C2C6-48F3-AFFB-1837D2F72DC7

Q48400110-5A6F1AEB-761E-41F3-AE23-F19F4BB4AFF5

Q48400110-96224E74-106D-404D-9B1B-BC65C409667D

Q48400110-A0A9BA0F-C8C4-433E-8E8D-900DD440CFD1

Q48400110-AE38618A-E55C-45D6-8847-9BEA98343E78

Q48400110-CEB24DDD-A21A-448B-8106-FBB96E3979EE

P304

Q48400110-AA8EFA85-B135-49E2-8387-146152858AAB

P31

Q48400110-34C7ABB2-C606-4E34-9EC8-C3D8688ECF6F

P356

Q48400110-0AB10089-6D8A-441D-B7A0-559134315EB6

P407

Q48400110-374E0545-D478-42C8-9236-B3AA0AD423D3

P433

Q48400110-5E61AB11-6A01-45B0-8891-354FF169E54C

P478

Q48400110-8783E2E3-4CFF-4306-8C08-DF8ADFEA04CA

P577

Q48400110-A7694CD2-45FA-4E8E-B686-22691EAF5658

P698

Q48400110-C14BAB9B-866B-491C-86FB-054AFCC99B04

P921

Q48400110-1ACC5050-DBA7-4B6A-ABDA-D9EBFBE228F7

Q48400110-8829A1A0-5519-4FF5-8C69-0ADC03678F66

P356

01.WNL.0000238518.34389.12

P1433

P1476

Creatine supplementation in Pa ...... rolled randomized pilot trial.

@en

P2093

Bender A

http://www.w3.org/2001/XMLSchema#string

Bender J

http://www.w3.org/2001/XMLSchema#string

Elstner M

http://www.w3.org/2001/XMLSchema#string

Gasser T

http://www.w3.org/2001/XMLSchema#string

Gekeler F

http://www.w3.org/2001/XMLSchema#string

Klopstock T

http://www.w3.org/2001/XMLSchema#string

Koch W

http://www.w3.org/2001/XMLSchema#string

Moeschl M

http://www.w3.org/2001/XMLSchema#string

Müller-Myhsok B

http://www.w3.org/2001/XMLSchema#string

Schombacher Y

http://www.w3.org/2001/XMLSchema#string

P304

1262-1264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/01.WNL.0000238518.34389.12

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17030762

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease